RefleXion, Telix partner on high-risk cancer treatments

By staff writers

July 8, 2020 -- Radiation therapy equipment developer RefleXion Medical and radiopharmaceutical company Telix Pharmaceuticals are investigating the clinical utility of combining their technologies for improving treatments for high-risk prostate and aggressive kidney cancers.

Under their strategic collaboration agreement, the firms will assess the potential of several new Telix PET tracers, including gallium-68 prostate-specific membrane antigen-11 for prostate cancer and Zr-89-girentuximab for kidney cancer, for guiding RefleXion's biology-guided radiotherapy technology.

Copyright © 2020

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking